Recurrent malignant melanoma of the uterine cervix treated with anti‑PD‑1 antibodies and anti‑CTLA‑4 antibodies: A case report

Sone,Kenbun; Kukita,Asako; Masui,Yuri; Yamada,Daisuke; Shinozaki‑Ushiku,Aya; Kawata,Akira; Taguchi,Ayumi; Miyamoto,Yuichiro; Tanikawa,Michihiro; Iriyama,Takayuki; Mori‑Uchino,Mayuyo; Tsuruga,Tetsushi; Osuga,Yutaka

doi:10.3892/mco.2022.2496

March-2022 Volume 16 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

March-2022 Volume 16 Issue 3

Full Size Image

Case Report Open Access

Recurrent malignant melanoma of the uterine cervix treated with anti‑PD‑1 antibodies and anti‑CTLA‑4 antibodies: A case report

Authors:
- Kenbun Sone
- Asako Kukita
- Yuri Masui
- Daisuke Yamada
- Aya Shinozaki‑Ushiku
- Akira Kawata
- Ayumi Taguchi
- Yuichiro Miyamoto
- Michihiro Tanikawa
- Takayuki Iriyama
- Mayuyo Mori‑Uchino
- Tetsushi Tsuruga
- Yutaka Osuga
View Affiliations / Copyright

Affiliations: Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo 113‑8655, Japan, Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo 113‑8655, Japan, Department of Pathology, The University of Tokyo Hospital, Tokyo 113‑8655, Japan

Copyright: © Sone et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Article Number: 63
|
Published online on: January 17, 2022

https://doi.org/10.3892/mco.2022.2496
Expand metrics +

Abstract

In 5% of female patients with malignant melanoma (MM), MM develops from the genital tract. MM of the cervix is particularly rare. In the present case report, a 73‑year‑old woman with stage ⅢC cervical MM underwent modified radical hysterectomy, bilateral salpingo‑oophorectomy and pelvic lymph node dissection. A total of 4 months after surgery, multiple metastases were found in the brain, lung, liver, lymph nodes and bone. The patient underwent γ‑knife surgery of the brain and received treatment with anti PD‑1 antibodies (nivolumab) and anti‑CTLA4 antibodies (ipilimumab); however, they were ineffective and the patient subsequently died. To the best of our knowledge, this is the first report of treatment using two types of immune checkpoint inhibitors administered to a patient with cervical MM. Taken together with previous reports, this case suggests that immune checkpoint inhibitors may be less effective in cervical MM than in cutaneous MM; however, the number of cases is small. Further development of biomarkers to stratify efficacy is required.

View Figures

View References

1	Kedzia W, Sajdak S, Kedzia H and Spaczyński M: Primary melanoma of the uterine cervix in a 19 year old woman case report. Ginekol Pol. 68:386–389. 1997.PubMed/NCBI(In Polish).
2	Myriokefalitaki E, Babbel B, Smith M and Ahmed AS: Primary malignant melanoma of uterine cervix FIGO IIa1: A case report with 40 months ongoing survival and literature review. Gynecol Oncol Case Rep. 5:52–54. 2013.PubMed/NCBI View Article : Google Scholar
3	Pusceddu S, Bajetta E, Carcangiu ML, Formisano B, Ducceschi M and Buzzoni R: A literature overview of primary cervical malignant melanoma: An exceedingly rare cancer. Crit Rev Oncol Hematol. 81:185–195. 2012.PubMed/NCBI View Article : Google Scholar
4	Yuan G, Wu L, Li B and An J: Primary malignant melanoma of the cervix: Report of 14 cases and review of literature:. Oncotarget. 8:73162–73167. 2017.PubMed/NCBI View Article : Google Scholar
5	Cantuaria G, Angioli R, Fernandez-Abril A and Penalver M: Primary malignant melanoma of the uterine cervix: Case report and review of the literature. Prim Care Update Ob Gyns. 5:159–160. 1998.PubMed/NCBI View Article : Google Scholar
6	Kristiansen SB, Anderson R and Cohen DM: Primary malignant melanoma of the cervix and review of the literature Gynecol. Oncol. 47:398–403. 1992.PubMed/NCBI View Article : Google Scholar
7	Noguchi T, Ota N, Mabuchi Y, Yagi S, Minami S, Okuhira H, Yamamoto Y, Nakamura Y and Ino K: A case of malignant melanoma of the uterine cervix with disseminated metastases throughout the vaginal wall. Case Rep Obstet Gynecol. 2017(5656340)2017.PubMed/NCBI View Article : Google Scholar
8	Jones HW III, Droegemueller W and Makowski EL: Primary melanocarcinoma of the cervix. Am J Obstet Gynecol. 111:959–963. 1971.PubMed/NCBI View Article : Google Scholar
9	Piura B: Management of primary melanoma of the female urogenital tract. Lancet Oncol. 9:973–981. 2008.PubMed/NCBI View Article : Google Scholar
10	Garbe C, Eigentler TK, Keilholz U, Hauschild A and Kirkwood JM: Systematic review of medical treatment for melanoma: Current status and future prospects. Oncologist. 16:5–24. 2011.PubMed/NCBI View Article : Google Scholar
11	Bajetta E, Del Vecchio M, Nova P, Fusi A, Daponte A, Sertoli MP, Queirolo P, Taveggia P, Bernengo MG, Legha SS, et al: Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol. 17:571–577. 2006.PubMed/NCBI View Article : Google Scholar
12	Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, et al: Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 372:30–39. 2015.PubMed/NCBI View Article : Google Scholar
13	Kim MS, Choi CH, Kim TJ, Lee JW, Lee J, Bae D and Kim BG: Primary malignant melanoma of the uterine cervix treated with pembrolizumab after radical surgery: A case report and literature review. Obstet Gynecol Sci. 61:524–528. 2018.PubMed/NCBI View Article : Google Scholar
14	Indini A, Di Guardo L, Cimminiello C, Lorusso D, Raspagliesi F and Del Vecchio M: Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: A preliminary experience. J Gynecol Oncol. 30(e94)2019.PubMed/NCBI View Article : Google Scholar
15	Anko M, Nakamura M, Kobayashi Y, Tsuji K, Nakada S, Nakamura Y, Funakoshi T, Banno K and Aoki D: Primary malignant melanoma of the uterine cervix or vagina was successfully treated with nivolumab. J Obstet Gynaecol Res. 46:190–195. 2020.PubMed/NCBI View Article : Google Scholar
16	D'Angelo SP, Larkin J, Sosman JA, Lebbé C, Brady B, Neyns B, Schmidt H, Hassel JC, Hodi FS, Lorigan P, et al: Efficacy and safety of nivolumab alone or in combination with Ipilimumab in patients with mucosal melanoma: A pooled analysis. J Clin Oncol. 35:226–235. 2017.PubMed/NCBI View Article : Google Scholar
17	NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) Cutaneous Melanoma Version 2.2019-March 12, 2019. https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf in 2019.
18	Torres-Cabala CA, Wang WL, Trent J, Yang D, Chen S, Galbincea J, Kim KB, Woodman S, Davies M, Plaza JA, et al: Correlation between KIT expression and KIT mutation in melanoma: A study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol. 22:1446–1456. 2009.PubMed/NCBI View Article : Google Scholar
19	Hodi FS, Chapman PB, Sznol M, Lao CD, Gonzalez R, Smylie M, Daniels GA, Thompson JA, Kudchadkar R, Sharfman W, et al: Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: Results from a North American expanded access program (CheckMate 218). Melanoma Res. 31:67–75. 2021.PubMed/NCBI View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Recurrent malignant melanoma of the uterine cervix treated with anti‑PD‑1 antibodies and anti‑CTLA‑4 antibodies: A case report

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Related Articles